A single high-intensity stereotactic body radiation therapy (SBRT) dose can be as effective as three slightly lower doses of radiation, revealed a new study led by Anurag Singh of Roswell Park Cancer Institute and presented at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting.
Stereotactic body radiation therapy (SBRT) is a specialized and highly targeted method of delivering radiotherapy, or radiation therapy, to treat cancer. This approach, used to treat many solid-tumor cancers, including lung, liver and kidney cancers, can mean greater convenience and quality of life for patients because it involves fewer individual treatments and can help to spare healthy tissue.
Working with colleagues from Roswell Park as well as collaborators from the Cleveland Clinic and Upstate New York Medical University, Dr. Singh undertook a phase II clinical study involving nearly 100 patients treated for early-stage non-small-cell lung cancer (NSCLC) between 2008 and 2015. The patients were randomly assigned to be treated through one of two established stereotactic radiation regimens: either a single dose of 30 grays (Gy) of radiation or 60 Gy delivered through three 20-Gy doses.
"Our goal is always to right-size treatment, and we're especially excited any time we can show that less treatment can be at least as effective as a more intense regimen, maybe even more so," says Dr. Singh, Professor of Oncology and Director of Radiation Research in the Department of Radiation Medicine at Roswell Park. "Our findings were surprising, because we previously thought that you would sacrifice some measure of efficacy by reducing radiation exposure to this extent. So we were thrilled that that is not the case."
"There are a lot of important implications here, in terms of patient convenience and quality of life — especially for those who don't live close to a cancer center — and the ability to combine radiation therapy with immunotherapy or surgery," adds Dr. Singh, who is currently leading or planning similar studies in other cancer disease sites.